期刊文献+

甲状腺乳头状癌组织趋化因子受体CXCR7和CCR5表达 被引量:1

EXPRESSIONS OF CHEMOKINE RECEPTORS CXCR7 AND CCR5 IN PAPILLARY THYROID CARCINOMA
下载PDF
导出
摘要 目的研究趋化因子受体7(CXCR7)和趋化因子受体5(CCR5)在甲状腺乳头状癌(PTC)组织表达及其与PTC不同病理特征的关系。方法应用免疫组化的方法,检测70例PTC、25例甲状腺滤泡腺瘤及11例癌旁(距肿瘤2cm以上)组织中CXCR7及CCR5的表达情况。结果 PTC组织CXCR7和CCR5表达阳性率高于甲状腺滤泡腺瘤及癌旁组织,差异有显著性(χ~2=23.94、26.48,P〈0.05);甲状腺滤泡腺瘤和癌旁组织中CXCR7和CCR5表达阳性率比较差异无显著性(P〉0.05)。Spearman相关分析显示,PTC组织中CXCR7和CCR5表达呈正相关(r=0.73,P〈0.05)。PTC组织中CXCR7和CCR5阳性表达与年龄、性别、TNM分期均无关(P〉0.05),仅与淋巴结转移情况有关(χ~2=22.493、21.476,P〈0.05)。结论 CXCR7及CCR5可能对PTC的发展及转移起一定的促进作用。 Objective To investigate the expressions of chemokine receptors CXCR7 and CCR5 and their association with different pathological characteristics in papillary thyroid carcinoma (PTC). Methods The expressions of CCR5 and CXCR7 in 70 cases of PTC, 25 of thyroid adenoma and 11 of paracancerous tissues (distance from tumor more than 2 cm) were detected using immunohistochemical method. Results The positive rate of expressions of CXCR7 and CCR5 in PTC was higher than that in thyroid follicular adenoma and paracancerous tissues, the difference was significant (X^2=23.94,26.48;P〈0.05). The difference in expressions of CXCR7 and CCR5 between thyroid follicular adenoma and paracancerous tissues was not significant (P〈0.05). Spearman correlation analysis showed that the expression of CXCR7 was positively correlated with CCR5 in PTC (r=0.73, P〈0.05). The positive expressions of CXCR7 and CCR5 in PTC tissue were not correlated with age, sex, and TNM stage (P〉0.05), which were associated only with lymph node metastasis (X^2 =22.493,21.476,P〈0.05). Conclusion CXCR7 and CCR5 possibly play a certain role in promoting the development and metastasis of papillary thyroid carcinoma.
出处 《齐鲁医学杂志》 2016年第4期404-406,410,共4页 Medical Journal of Qilu
关键词 甲状腺乳头状癌 趋化因子受体7 趋化因子受体5 papillary thyroid carcinoma chemokine receptor 7 chemokine receptor 5
  • 相关文献

参考文献20

  • 1KAZAURE H S, ROMAN S A, SOSA J A. Aggressive va- riants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738patients[J]. Annals of Surgical Oncology, 2012,19 (6) : 1874- 1880.
  • 2WANG W D, GU J L, SHANG J B, et al. Correlation analy sis on central lymph node metastasis in 276 patients with cN0 papillary thyroid carcinoma[J]. International Journal of Clini cal and Experimental Pathology, 2013,6(3):510-515.
  • 3MEIJER J, OGINK J, ROOS E. Effect of the chemokine re- ceptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo[J]. British Journal of Cancer, 2008,99(9) =1493-1501.
  • 4KEBEBEW E, CLARK O H. Differentiated thyroid cancer: "complete" rational approach[J]. World Journal of Surgery, 2000,24(8) : 942-951.
  • 5LI Q S, CHEN S H, XIONG H H, et al. Papillary thyroid carcinoma on sonography[J]. Clinical Imaging, 2010,34 (2) : 121 -126.
  • 6周庚寅,白艳花,觉道健一.甲状腺乳头状癌的病理诊断及遗传学特点[J].临床与实验病理学杂志,2010,26(2):131-134. 被引量:40
  • 7赵刚,吴剑涓.趋化因子受体拮抗剂的研究进展[J].天津药学,2013,25(2):52-57. 被引量:4
  • 8SCHOLTEN D J, CANALS M, MAUSSANG D, et al. Phar macological modulation of chemokine receptor function[J].British Journal of Pharmacology, 2012,165 (6) : 1617-1643.
  • 9LAZENNEC G, RICHMOND A. Chemokines and chemokine receptors: new insights into cancer related inflammation[J]. Trends in Molecular Medicine, 2010,16(3):133-144.
  • 10于冰,邵翠华,徐金娥.趋化因子12及其受体对胎盘血管形成及免疫耐受的作用[J].青岛大学医学院学报,2015,51(3):374-376. 被引量:3

二级参考文献69

  • 1杨昀,邹丽,何明.CXCL12/CXCR4在绒毛外滋养细胞中的表达及其意义[J].现代妇产科进展,2006,15(7):528-530. 被引量:6
  • 2杨昀,邹丽,王轶英.SDF-1/CXCR4在滋养层细胞中的表达及其在母胎免疫耐受中的作用[J].细胞与分子免疫学杂志,2006,22(5):603-605. 被引量:4
  • 3LiVolsi V A,Mazzaferri E L,Schneider A B,et al.Papillary carcinoma[M]//DeLellis R A,Lloyd R V,Heitz P U,Eng C,et al,eds.World Health Organization classification of tumours,pathology and genetics of tumours of endocrine organs.Lyon:IARC Press,2004:57-66.
  • 4唐卫华,觉道建一.甲状腺乳头状癌[M]//周庚寅,觉道建一主编.甲状腺病理与临床.北京:人民卫生出版社,2005:137-57.
  • 5Tunio GM,Hirota S,Nomura S,Kitamura Y.Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer[J].Arch Pathol Lab Med,1998,122(12):1087-90.
  • 6Bai Y,Zhou G,Nakamura M,et al.Survival impact of psammoma body,stromal calcification,and bone formation in papillary thyroid carcinoma[J].Mod Pathol,2009,22(7):887-94.
  • 7Johannessen J V,Sobrinho-Simoes M.The origin and significance of thyroid psammoma bodies[J].Lab Invest,1980,43(3):287-96.
  • 8Nasr M R,Mukhopadhyay S,Zhang S,Katzenstein AL.Immunohistochemical markers in diagnosis of papillary thyroid carcinoma:Utility of HBME1 combined with CK19 immunostaining[J].Mod Pathol,2006,19(12):1631-7.
  • 9Barroeta J E,Baloch Z W,Lal P,et al.Diagnostic value of differential expression of CK19,Galectin-3,HBME-1,ERK,RET,and p16 in benign and malignant follicular-derived lesions of the thyroid:an immunohistochemical tissue microarray analysis[J].Endocr Pathol,2006,17(3):225-34.
  • 10Williams E D.Guest Editorial:Two Proposals Regarding the Terminology of Thyroid Tumors[J].Int J Surg Pathol,2000,8(3):181-3.

共引文献52

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部